A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Trial Details

NCT ID
NCT06697184
Phase
PHASE1 / PHASE2
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Sonrotoclax
  • Zanubrutinib
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Fort Wayne, Indiana, United States|41.1306,-85.12886
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Stable Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • Adequate organ function and no very recent transfusion or blood growth factor
  • Participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the dura…
  • Only for participants with Chronic Lymphocytic Leukemia (CLL):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →